This is a translation from the Swedish press release 2019-01-28 Kancera AB (Nasdaq First North: KAN) today announces that intermediate goals have been achieved prior to the planned start of clinical trials with the drug candidate KAND567 to demonstrate reduced tissue damage...
Read MoreThis is a translation of a pressrelease in Swedish from December 3rd 2018. Kancera AB announced today that the company has entered into an Research and Option agreement with Grünenthal, a leading pharmaceutical company in pain research and management. As part of...
Read MoreHere follows a translation of a Swedish press release from November 23th 2018. Kancera announces that terms have been prepared for a shareholders' decision on investment in the company by Global Corporate Finance (GCF), New York. The investment, which covers a maximum...
Read MoreKancera AB today announced that the article entitled "Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination" has been published by researchers from Karolinska Institutet and Kancera AB in the journal Nature Communications1. The article documents the molecular mechanisms that give the small...
Read MoreKancera AB (publ) hereby reports on project activities and status for the preparation and implementation of a clinical study in cardiovascular inflammation associated with myocardial infarction. In the cancer area, it is announced that the research project funded by SWElife has been...
Read MoreThis is a translation of the Swedish press release published 2018-07-06. Kancera AB (publ) hereby announces that unique blockers (antagonists) of the Fractalkine system have been patented. Kancera intends to further develop a new drug candidate from the patented antagonists, and this...
Read MoreKancera AB intends to provide new information about the company's pharmaceutical projects during April in a prospectus that forms part of a proposed new share issue. For this reason, Kancera now communicates the following information: Kanceras HDAC6 inhibitor KAN0440262...
Read MoreKancera AB (publ) hereby reports results from a Phase I study in healthy subjects with the immunoregulating drug candidate KAND567. The study shows that KAND567 is safe and well-tolerated up to 500 mg twice daily for 7 days. The...
Read MoreKancera AB (publ) reports that the Phase I study in the Fractalkine project has been completed in accordance with study protocols. In the study, drug characteristics, safety and tolerability have been documented for KAND567 in 62 healthy subjects. The...
Read MoreKancera AB (publ) has previously announced that the company controls patents and rights to the Fractalkine project, including KAND567, in all diseases except lung diseases. Agreements with AstraZeneca AB and Acturum Real Estate AB now give Kancera AB full...
Read More